www.diseases-diagnosis.com Homepage Diseases Symptoms Diseases Diagnosis Diseases Treatment Diseases Living Care Diseases Prevention Diseases Research
Monday, September 18th, 2017
Table of Contents

1 Introduction
 [F] Diseases Research  / PubMed Research Articles  /
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.




JAMA 2017 Sep 12; 318(10)


Giuliano AE1; Ballman KV2; McCall L3; Beitsch PD4; Brennan MB5; Kelemen PR6; Ollila DW7; Hansen NM8; Whitworth PW9; Blumencranz PW10; Leitch AM11; Saha S12; Hunt KK13; Morrow M14;

Author Information
  • 1Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California.
  • 2Alliance Statistics and Data Center, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, New York.
  • 3Alliance Statistics and Data Center, Duke University, Durham, North Carolina.
  • 4Dallas Surgical Group, Dallas, Texas.
  • 5Clinical Research Unit/TRIO-US Network, Jonsson Comprehensive Cancer Center, University of California, Los Angeles.
  • 6Ashikari Breast Center, Dobbs Ferry, New York.
  • 7Department of Surgery, University of North Carolina, Chapel Hill.
  • 8Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • 9Nashville Breast Center, Nashville, Tenessee.
  • 10Morton Plant Hospital, Clearwater, Florida.
  • 11Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas.
  • 12MacLaren Regional Medical Center, Michigan State University, Flint.
  • 13Department of Breast Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston.
  • 14Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.


Importance: The results of the American College of Surgeons Oncology Group Z0011 (ACOSOG Z0011) trial were first reported in 2005 with a median follow-up of 6.3 years. Longer follow-up was necessary because the majority of the patients had estrogen receptor-positive tumors that may recur later in the disease course (the ACOSOG is now part of the Alliance for Clinical Trials in Oncology).

Objective: To determine whether the 10-year overall survival of patients with sentinel lymph node metastases treated with breast-conserving therapy and sentinel lymph node dissection (SLND) alone without axillary lymph node dissection (ALND) is noninferior to that of women treated with axillary dissection.

Design, Setting, and Participants: The ACOSOG Z0011 phase 3 randomized clinical trial enrolled patients from May 1999 to December 2004 at 115 sites (both academic and community medical centers). The last date of follow-up was September 29, 2015, in the ACOSOG Z0011 (Alliance) trial. Eligible patients were women with clinical T1 or T2 invasive breast cancer, no palpable axillary adenopathy, and 1 or 2 sentinel lymph nodes containing metastases.

Interventions: All patients had planned lumpectomy, planned tangential whole-breast irradiation, and adjuvant systemic therapy. Third-field radiation was prohibited.

Main Outcomes and Measures: The primary outcome was overall survival with a noninferiority hazard ratio (HR) margin of 1.3. The secondary outcome was disease-free survival.

Results: Among 891 women who were randomized (median age, 55 years), 856 (96%) completed the trial (446 in the SLND alone group and 445 in the ALND group). At a median follow-up of 9.3 years (interquartile range, 6.93-10.34 years), the 10-year overall survival was 86.3% in the SLND alone group and 83.6% in the ALND group (HR, 0.85 [1-sided 95% CI, 0-1.16]; noninferiority P = .02). The 10-year disease-free survival was 80.2% in the SLND alone group and 78.2% in the ALND group (HR, 0.85 [95% CI, 0.62-1.17]; P = .32). Between year 5 and year 10, 1 regional recurrence was seen in the SLND alone group vs none in the ALND group. Ten-year regional recurrence did not differ significantly between the 2 groups.

Conclusions and Relevance: Among women with T1 or T2 invasive primary breast cancer, no palpable axillary adenopathy, and 1 or 2 sentinel lymph nodes containing metastases, 10-year overall survival for patients treated with sentinel lymph node dissection alone was noninferior to overall survival for those treated with axillary lymph node dissection. These findings do not support routine use of axillary lymph node dissection in this patient population based on 10-year outcomes.

Trial Registration: clinicaltrials.gov Identifier: NCT00003855.




Publication Type: Journal Article

This article is licensed under the the National Library of Medicine License. It uses material from the PubMed National Library of Medicine Data.

Last Modified:   2016-03-27

All informatin on the site is © www.diseases-diagnosis.com 2002-2016. Last revised: March 27, 2016
Are you interested in our site or/and want to use our information? please read how to contact us and our copyrights.
To let us provide you with high quality information, you can help us by making a more or less donation: